[Three-year follow-up results of the first clinical study on the daily and twice-weekly administrations of rifampicin, investigated by the Tuberculosis Research Committee, Ryoken (author's transl)].
D005500:Follow-Up Studies; D006801:Humans; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D012293:Rifampin